Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
obesity drugs
Biotech
Novo hails ‘remarkable’ weight loss result for experimental pill
Novo linked the candidate to 13.1% weight loss after 12 weeks—and highlighted the potential for further reductions in longer trials.
Nick Paul Taylor
Sep 11, 2024 11:02am
Zealand Pharma’s GLP-1/GLP-2 agonist tied to 8.3% weight loss
Sep 10, 2024 10:45am
Lilly, Haya ink $1B biobuck obesity pact to search dark genome
Sep 4, 2024 8:00am
MBX files for IPO to take challenger to Ascendis into phase 3
Aug 26, 2024 9:40am
Arrowhead dips toes into obesity pond with 2 preclinical assets
Aug 14, 2024 3:50pm
Rivus’ phase 2 obesity-related heart failure trial hits endpoint
Aug 13, 2024 8:57am